Royce & Associates LP lowered its position in SI-BONE, Inc. (NASDAQ:SIBN – Free Report) by 24.1% during the 3rd quarter, Holdings Channel.com reports. The firm owned 110,000 shares of the company’s stock after selling 35,000 shares during the quarter. Royce & Associates LP’s holdings in SI-BONE were worth $1,538,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently made changes to their positions in the company. Impax Asset Management Group plc increased its position in SI-BONE by 41.3% in the 3rd quarter. Impax Asset Management Group plc now owns 758,521 shares of the company’s stock valued at $10,604,000 after acquiring an additional 221,604 shares during the period. Harbor Capital Advisors Inc. increased its holdings in shares of SI-BONE by 222.5% during the third quarter. Harbor Capital Advisors Inc. now owns 620,490 shares of the company’s stock valued at $8,674,000 after purchasing an additional 428,110 shares during the period. Essex Investment Management Co. LLC bought a new stake in shares of SI-BONE during the third quarter valued at about $2,342,000. Diversified Trust Co lifted its holdings in SI-BONE by 27.6% in the third quarter. Diversified Trust Co now owns 27,160 shares of the company’s stock worth $380,000 after purchasing an additional 5,875 shares during the period. Finally, SG Americas Securities LLC acquired a new position in SI-BONE during the 3rd quarter valued at about $353,000. Institutional investors own 98.11% of the company’s stock.
SI-BONE Trading Down 0.3 %
Shares of NASDAQ:SIBN opened at $12.32 on Wednesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The stock has a market capitalization of $516.70 million, a price-to-earnings ratio of -13.39 and a beta of 1.22. SI-BONE, Inc. has a 1-year low of $11.76 and a 1-year high of $21.70. The company has a 50 day moving average price of $13.91 and a 200 day moving average price of $14.26.
Insider Activity
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of SI-BONE in a research note on Wednesday, November 13th. Morgan Stanley decreased their price target on SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, Truist Financial boosted their price objective on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $23.00.
Read Our Latest Analysis on SI-BONE
About SI-BONE
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
Recommended Stories
- Five stocks we like better than SI-BONE
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- Investing In Automotive Stocks
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 3 Hot Stock Trends to Ride Into 2025
Want to see what other hedge funds are holding SIBN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SI-BONE, Inc. (NASDAQ:SIBN – Free Report).
Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.